Total B2C revenue grew by 25 per cent YoY in H1FY23 & 22 per cent in Q2FY23
Metropolis Healthcare has announced its unaudited consolidated financial results for the second quarter of financial year 2023.
Q2FY23 key highlights
- Wellness revenue increased by 40 per cent YoY to Rs 33 crores
- EBITDA margin (Before CSR & ESOP) stood at 27.6 per cent
- Specialised tests contributed 40 per cent to the Non-COVID revenue Q2FY23
Key highlights for core business#
- Total revenues grew by 12.4 per cent YoY
- Specialised tests revenues grew by 15 per cent YoY
- Wellness tests revenues grew by 36 per cent YoY
- Patient & tests volumes grew by 10 per cent YoY
Q2FY23 financial highlights
- Rs 288 crores: Non-COVID revenue*
- Rs 83 crores: EBITDA (Before CSR & ESOP)
- Rs 41 crores: Profit after tax
Ameera Shah, Promoter and Managing Director, Metropolis Healthcare said, “I am extremely pleased to share that we have recorded highest ever quarterly revenue* with 16 per cent growth on year-on-year basis. With accelerated shift from the unorganised to the organised sector coupled with increased health awareness amongst customers and a trusted scientific image with medical fraternity, we expect the revenues growth to improve and margins to sustain at the pre-COVID levels. We have seen growth in our volumes & patient count and with increased investments in digital & marketing, manpower & customer experience initiatives, we are optimistic of sustaining the growth going forward. Our revenue contribution from wellness segment has increased to 12 per cent in Q2FY23 & has witnessed a healthy growth of 40 per cent on YoY basis; a testimony to our on-ground efforts and the acceptance of Metropolis Brand in the minds of consumers and medical fraternity.”
*Revenue excl. COVID PCR & COVID allied tests
#Excluding hi-tech and government contracts